Earnings summaries and quarterly performance for Mural Oncology.
Executive leadership at Mural Oncology.
Board of directors at Mural Oncology.
Research analysts covering Mural Oncology.
Recent press releases and 8-K filings for MURA.
Mural Oncology plc Acquisition by XOMA Royalty Corporation Completed
MURA
M&A
Delisting/Listing Issues
Board Change
- Mural Oncology plc announced the completion of its acquisition by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, effective December 5, 2025.
- Each Mural Oncology ordinary share was acquired for $2.035 in cash, with distributions to shareholders expected to be completed by December 19, 2025.
- The company's shares were delisted from the Nasdaq Global Market effective 8:00 pm (U.S. Eastern Time) on December 4, 2025, and Mural Oncology intends to suspend its reporting obligations.
- The acquisition resulted in a change in control and significant board and management changes, including the appointment of Owen Hughes as Chief Executive Officer and Secretary.
2 days ago
Mural Oncology Acquisition Sanctioned by High Court
MURA
M&A
Delisting/Listing Issues
Takeover Bid
- The High Court of Ireland has sanctioned the scheme of arrangement for XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, to acquire the entire issued share capital of Mural Oncology plc.
- The Acquisition is expected to become effective on December 5, 2025.
- December 4, 2025, is anticipated to be the last date for trading of Mural Shares on Nasdaq, with cancellation of admission to trading on the Nasdaq Global Market expected to occur with effect from 8:00 pm (U.S. Eastern Time) on that day.
- Distribution of cash consideration to Scheme Shareholders is expected to be completed by no later than December 19, 2025.
4 days ago
Mural Oncology plc Shareholders Approve Acquisition by XOMA Royalty Subsidiary
MURA
M&A
Proxy Vote Outcomes
Takeover Bid
- On October 24, 2025, Mural Oncology plc shareholders approved the proposed acquisition by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation.
- At the Scheme Meeting, Proposal 1 (Scheme of Arrangement) was approved with 10,103,706 votes For.
- At the Extraordinary General Meeting, shareholders approved Proposal 1 (Scheme of Arrangement) with 10,607,228 votes For and Proposal 2 (amendment to articles of association) with 10,647,967 votes For.
- The acquisition is expected to be completed during the fourth quarter of 2025, pending customary closing conditions and sanction by the High Court of Ireland.
Oct 24, 2025, 8:35 PM
Mural Oncology Merger Investigation Announced
MURA
M&A
Legal Proceedings
Takeover Bid
- Monteverde & Associates PC is investigating the sale of Mural Oncology plc (NASDAQ:MURA) to XOMA Royalty Corporation.
- Under the terms of the proposed transaction, Mural shareholders are expected to receive $2.035 in cash per share, with a potential additional $0.205 per share under certain conditions.
Sep 22, 2025, 9:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more